欧莱雅首席执行官尼古拉斯·希埃罗尼穆斯表示，GLP-1减肥药使用率上升对公司的美容和护肤销售产生了影响1。他称这一现象"对我们来说是一个非常重要的现象"1，并指出GLP-1的使用"对美容消费和特别是护肤消费产生了影响"1。
公司旗下品牌SkinCeuticals和Kiehl's已推出新产品，这些产品"被设计用于与GLP-1及其对皮肤松弛的副作用配合使用"1。欧莱雅第三季度（截至9月）销售额增长7.7%，超过分析师预期1。此外，欧莱雅在去年12月将其在皮肤科公司Galderma的股份增加至20%1。
L'Oreal's chief executive Nicholas Hieronimus has acknowledged that the rising use of GLP-1 weight loss medications is affecting the company's beauty and skincare business 1. Hieronimus described GLP-1 usage as "a very important phenomenon" for the firm, noting that it "has had an impact on beauty consumption and particularly on skincare consumption" 1.
In response to this market shift, L'Oreal has developed targeted products to address the side effects of rapid weight loss induced by these drugs. The company's brands SkinCeuticals and Kiehl's have launched offerings "designed to work with GLP-1 and its side effects on skin laxity" 1. The company also increased its stake in dermatology firm Galderma to 20 percent in December of last year 1.
L'Oreal delivered strong third-quarter results, with sales growth of 7.7 percent for the period ending in September, surpassing analyst expectations 1.
评论
还没有评论，欢迎留下第一条。